Publikationen von A. Ullrich

Zhang, Y. X.; Knyazev, P. G.; Cheburkin, Y. V.; Sharma, K.; Knyazev, Y. P.; Orfi, L.; Szabadkai, I.; Daub, H.; Keri, G.; Ullrich, A.: AXL is a potential target for therapeutic intervention in breast cancer progression. Cancer Research 68 (6), S. 1905 - 1915 (2008)

Stenzel, E.; Muller, M.; Willers, R.; Ullrich, A.; Gabbert, H. E.; Engers, R.: Overexpression of Gas6 and Axl in prostate cancer. Onkologie 31 (Suppl. Suppl. 1), S. 182 - 182 (2008)

Horvat-Bröcker, A.; Reinhard, J.; Illes, S.; Paech, T.; Zoidl, G.; Harroch, S.; Distler, C.; Knyazev, P.; Ullrich, A.; Faissner, A.: RECEPTOR PROTEIN TYROSINE PHOSPHATASES ARE EXPRESSED BY CYCLING RETINAL PROGENITOR CELLS AND INVOLVED IN NEURONAL DEVELOPMENT OF MOUSE RETINA. Neuroscience 152 (3), S. 618 - 645 (2008)

Hutterer, M.; Knyazev, P.; Abate, A.; Reschke, M.; Maier, H.; Stefanova, N.; Knyazeva, T.; Barbieri, V.; Reindl, M.; Muigg, A. et al.; Kostron, H.; Stockhammer, G.; Ullrich, A.: Axl and growth arrest - Specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clinical Cancer Research 14 (1), S. 130 - 138 (2008)

Jackisch, C.; Ruschoff, J.; Ullrich, A.: Development of targeted therapies in ErbB2-positive breast cancer. Breast Care 3 (Suppl. Suppl. 1), S. 3 - 6 (2008)

Ruhe, J. E.; Streit, S.; Hart, S.; Wong, C. H.; Specht, K.; Knyazev, P.; Knyazeva, T.; Tay, L. S.; Loo, H. L.; Foo, P. et al.; Wong, W.; Pok, S.; Lim, S. J.; Ong, H.; Luo, M.; Ho, H. V.; Peng, K.; Lee, T. C.; Bezler, M.; Mann, C.; Gaertner, S.; Hoefler, H.; Iacobelli, S.; Peter, S.; Tay, A.; Brenner, S.; Venkatesh, B.; Ullrich, A.: Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Research 67 (23), S. 11368 - 11376 (2007)

Ullrich, A.: Interference with cellular signal transduction mechanisms as basis for the development of novel cancer therapies. Abstracts of the 32nd FEBS Congress, D3-L3, S. 39 - 39 (2007)

Steták, A.; Veress, R.; Ovádi, J.; Csermely, P.; Kéri, G.; Ullrich, A.: Nuclear Translocation of the Tumor Marker Pyruvate Kinase M2 Induces Programmed Cell Death. Cancer Research 67 (4), S. 1602 - 1608 (2007)

Strebhardt, K.; Ullrich, A.: Another look at imatinib mesylate. New England Journal of Medicine 355 (23), S. 2481 - 2482 (2006)

Ramirez, B. S.; Pestana, E. S.; Hidalgo, G. G.; Garcia, T. H.; Rodriguez, R. P.; Ullrich, A.; Fernandez, L. E.: Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. International Journal of Cancer 119 (9), S. 2190 - 2199 (2006)

Wang, Y. G.; Du, D.; Fang, L. H.; Yang, G.; Zhang, C. Y.; Zeng, R.; Ullrich, A.; Lottspeich, F.; Chen, Z. J.: Tyrosine phosphorylated Par3 regulates epithelial tight junction assembly promoted by EGFR signaling. EMBO Journal 25 (21), S. 5058 - 5070 (2006)

Bhattacharya, I.; Ullrich, A.: Endothelin-1 inhibits adipogenesis: Role of phosphorylation of Akt and ERK1/2. FEBS Letters 580 (24), S. 5765 - 5771 (2006)

Abate, A.; Hutterer, M.; Mair, H.; Stefanova, N.; Kostron, H.; Knyazev, P.; Ullrich, A.; Stockhammer, G.: The receptor tyrosine kinase Axl is widely expressed in gliomas of various histology. Neuro-Oncology 8 (4), S. 321 - 322 (2006)

Streit, S.; Ruhe, J. E.; Knyazev, P.; Knyazeva, T.; Iacobelli, S.; Peter, S.; Hoefler, H.; Ullrich, A.: PTP-PEST phosphatase variations in human cancer. Cancer Genetics and Cytogenetics 170 (1), S. 48 - 53 (2006)

Tanner, B.; Hasenclever, D.; Stern, K.; Schormann, W.; Bezler, M.; Hermes, M.; Brulport, M.; Bauer, A.; Schiffer, I. B.; Gebhard, S. et al.; Schmidt, M.; Steiner, E.; Sehouli, J.; Edelmann, J.; Lauter, J.; Lessig, R.; Krishnamurthi, K.; Ullrich, A.; Hengstler, J. G.: ErbB-3 predicts survival in ovarian cancer. Journal of Clinical Oncology 24 (26), S. 4317 - 4323 (2006)

Ruhe, J. E.; Streit, S.; Hart, S.; Ullrich, A.: EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. Cellular Signalling 18 (9), S. 1515 - 1527 (2006)

Thussbas, C.; Nahrig, J.; Streit, S.; Bange, J.; Kriner, M.; Kates, R.; Ulm, K.; Kiechle, M.; Hoefler, H.; Ullrich, A. et al.; Harbeck, N.: FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. Journal of Clinical Oncology 24 (23), S. 3747 - 3755 (2006)

Streit, S.; Mestel, D. S.; Schmidt, M.; Ullrich, A.; Berking, C.: FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients. British Journal of Cancer 94 (12), S. 1879 - 1886 (2006)

Stadler, C. R.; Knyazev, P.; Bange, J.; Ullrich, A.: FGFR4 GLY388 isotype suppresses motility of MDA-MB-231 breast cancer cells by EDG-2 gene repression. Cellular Signalling 18 (6), S. 783 - 794 (2006)

Anders, L.; Mertins, P.; Lammich, S.; Murgia, M.; Hartmann, D.; Saftig, P.; Haass, C.; Ullrich, A.: Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity. Molecular and Cellular Biology 26 (10), S. 3917 - 3934 (2006)